Hiroshi Sakai Selected Research

Cyclophosphamide (Cytoxan)

1/2016	Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
2/2009	Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroshi Sakai Research Topics

Disease

45	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 05/2002
21	Neoplasms (Cancer) 04/2024 - 01/2002
21	Heart Failure 01/2020 - 12/2004
11	Lung Neoplasms (Lung Cancer) 01/2023 - 10/2006
8	Hepatocellular Carcinoma (Hepatoma) 04/2024 - 10/2014
7	Disease Progression 01/2021 - 12/2009
6	Hemorrhage 09/2023 - 01/2018
6	Vomiting 01/2022 - 02/2009
6	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2019 - 12/2009
6	Glaucoma 03/2012 - 09/2002
5	Nausea 01/2022 - 02/2009
4	Edema (Dropsy) 04/2024 - 10/2008
4	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2011 - 07/2006
3	Wounds and Injuries (Trauma) 12/2022 - 01/2004
3	Diarrhea 01/2022 - 05/2019
3	Brain Neoplasms (Brain Tumor) 01/2022 - 02/2010
3	Neutropenia 01/2021 - 01/2014
3	Febrile Neutropenia 05/2019 - 01/2014
3	Cardiovascular Diseases (Cardiovascular Disease) 04/2008 - 07/2006
2	Ascites 03/2024 - 11/2016
2	Pleural Effusion (Pleural Effusions) 03/2024 - 01/2022
2	Respiratory Insufficiency (Respiratory Failure) 03/2024 - 01/2017
2	Hypertension (High Blood Pressure) 02/2024 - 08/2007
2	Myocardial Infarction 01/2023 - 01/2020
2	Inflammation (Inflammations) 01/2022 - 07/2003
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2017 - 06/2012
2	Thrombocytopenia (Thrombopenia) 01/2017 - 01/2014
2	Anorexia 01/2017 - 01/2017
2	Coronary Artery Disease (Coronary Atherosclerosis) 03/2016 - 04/2007
2	Radiation Pneumonitis 02/2016 - 01/2014
2	Adenocarcinoma 01/2016 - 12/2010
2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 02/2015 - 01/2013
2	Hepatolenticular Degeneration (Wilson's Disease) 12/2013 - 03/2011
2	Pancreatic Neoplasms (Pancreatic Cancer) 11/2011 - 08/2011
2	Meningeal Carcinomatosis 02/2010 - 11/2006
2	Open-Angle Glaucoma (Glaucoma, Open Angle) 12/2008 - 04/2004

Drug/Important Bio-Agent (IBA)

14	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 12/2004
13	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2020 - 02/2006
12	NivolumabIBA 01/2023 - 01/2016
7	Tyrosine Kinase InhibitorsIBA 02/2024 - 01/2017
7	ErbB Receptors (EGF Receptor)IBA 12/2019 - 01/2016
7	Docetaxel (Taxotere)FDA Link 09/2019 - 02/2004
6	pro-brain natriuretic peptide (1-76)IBA 12/2020 - 04/2007
6	Carboplatin (JM8)FDA LinkGeneric 01/2016 - 02/2004
5	IpilimumabIBA 01/2023 - 11/2019
5	B7-H1 AntigenIBA 01/2022 - 03/2019
5	AnthracyclinesIBA 01/2016 - 06/2003
5	Latanoprost (Xalatan)FDA Link 01/2009 - 09/2002
4	tepotinibIBA 02/2024 - 01/2020
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
4	PlatinumIBA 05/2019 - 10/2006
4	Palonosetron (Aloxi)FDA Link 02/2019 - 02/2009
4	Biomarkers (Surrogate Marker)IBA 02/2018 - 01/2011
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2014 - 04/2004
4	AldosteroneIBA 08/2007 - 12/2004
3	pembrolizumabIBA 12/2021 - 03/2019
3	CytokinesIBA 01/2020 - 10/2007
3	Gemcitabine FDA Link 06/2019 - 08/2011
3	SteroidsIBA 01/2017 - 09/2005
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2016 - 09/2005
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016 - 06/2003
3	Messenger RNA (mRNA)IBA 08/2011 - 02/2006
3	AdiponectinIBA 04/2008 - 07/2007
2	CreatinineIBA 04/2024 - 01/2022
2	LigandsIBA 05/2023 - 03/2019
2	Clopidogrel (Plavix)FDA Link 01/2023 - 01/2020
2	Atrial Natriuretic Factor (ANF)IBA 01/2020 - 04/2008
2	Hormones (Hormone)IBA 01/2020 - 02/2018
2	necitumumabIBA 06/2019 - 01/2019
2	Monoclonal AntibodiesIBA 03/2019 - 01/2016
2	Gefitinib (Iressa)FDA Link 07/2018 - 11/2006
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016 - 02/2009
2	Granisetron (Kytril)FDA LinkGeneric 01/2016 - 02/2009
2	Bevacizumab (Avastin)FDA Link 01/2016 - 06/2012
2	DystrophinIBA 02/2015 - 01/2013
2	130-nm albumin-bound paclitaxelIBA 01/2014 - 07/2013
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2014 - 12/2009
2	ParaffinIBA 11/2011 - 12/2010
2	MicroRNAs (MicroRNA)IBA 11/2011 - 12/2010
2	Formaldehyde (Formol)FDA Link 11/2011 - 12/2010
2	Topotecan (Hycamtin)FDA LinkGeneric 10/2011 - 02/2011
2	ReninIBA 01/2011 - 06/2007
2	S-1 plus cisplatinIBA 05/2010 - 12/2004
2	potassium oxonateIBA 05/2010 - 12/2004
2	TegafurIBA 05/2010 - 12/2004
2	brinzolamide (Azopt)FDA Link 01/2009 - 12/2008
2	dorzolamide (Trusopt)FDA LinkGeneric 01/2009 - 12/2005

Therapy/Procedure

22	Drug Therapy (Chemotherapy) 01/2023 - 05/2002
20	Therapeutics 10/2023 - 03/2003
6	Chemoradiotherapy 01/2020 - 04/2012
5	Liver Transplantation 04/2024 - 05/2023
5	Percutaneous Coronary Intervention 09/2023 - 01/2022
5	Radiotherapy 01/2022 - 02/2004
5	Lasers (Laser) 12/2018 - 01/2003
3	Immunotherapy 03/2024 - 01/2017
3	Hepatectomy 02/2024 - 04/2015
3	Aftercare (After-Treatment) 02/2016 - 04/2004
2	Stents 01/2022 - 01/2020
2	Oral Administration 01/2022 - 05/2010
2	Consolidation Chemotherapy 04/2012 - 02/2004